Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Triple Negative Breast Neoplasms 1Lung Neoplasms 1Lung Diseases 1Esophageal Squamous Cell Carcinoma 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Carboplatin 49Pemetrexed 38Cisplatin 34Radiotherapy 32Docetaxel 31Gemcitabine 25Paclitaxel 24Nivolumab 18pembrolizumab 15Etoposide 15Radiosurgery 13Erlotinib Hydrochloride 11Bevacizumab 11Magnetic Resonance Spectroscopy 10Vinorelbine 9Radiation 9Cyclophosphamide 7durvalumab 6Gefitinib 6Fluorodeoxyglucose F18 6Celecoxib 6atezolizumab 5Oxaliplatin 5Irinotecan 5Immunoglobulin G 5Drug Therapy 5Disulfides 5Dexamethasone 5Chemotherapy, Adjuvant 5vandetanib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lung Neoplasms × sitravatinib × Clear all
NCT04925986 2025-04-17

Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC

Yale University

Phase 2 Terminated
9 enrolled 15 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡